MX2023008454A - Derivados sintéticos de ácido ursólico y métodos de uso de estos. - Google Patents

Derivados sintéticos de ácido ursólico y métodos de uso de estos.

Info

Publication number
MX2023008454A
MX2023008454A MX2023008454A MX2023008454A MX2023008454A MX 2023008454 A MX2023008454 A MX 2023008454A MX 2023008454 A MX2023008454 A MX 2023008454A MX 2023008454 A MX2023008454 A MX 2023008454A MX 2023008454 A MX2023008454 A MX 2023008454A
Authority
MX
Mexico
Prior art keywords
synthetic
methods
acid derivatives
ursolic acid
compounds
Prior art date
Application number
MX2023008454A
Other languages
English (en)
Inventor
Xin Jiang
Melean Visnick
Jr Robert M Kral
Ha Do
Haizhou Sun
Original Assignee
Reata Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reata Pharmaceuticals Inc filed Critical Reata Pharmaceuticals Inc
Publication of MX2023008454A publication Critical patent/MX2023008454A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

En la presente se divulgan compuestos de la Fórmula: (ver fórmula) (I-A), en donde las variables se definen en la presente. También se proporcionan composiciones farmacéuticas de estos. En algunos aspectos, los compuestos y las composiciones proporcionados en la presente pueden utilizarse como moduladores antioxidantes de la inflamación. En algunos aspectos, la presente divulgación proporciona métodos en donde los compuestos y las composiciones descritos en la presente se utilizan para el tratamiento de enfermedades y trastornos asociados con la inflamación y el cáncer.
MX2023008454A 2021-01-18 2022-01-18 Derivados sintéticos de ácido ursólico y métodos de uso de estos. MX2023008454A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163199694P 2021-01-18 2021-01-18
PCT/US2022/012831 WO2022155614A1 (en) 2021-01-18 2022-01-18 Synthetic ursolic acid derivatives and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2023008454A true MX2023008454A (es) 2023-08-07

Family

ID=80222334

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023008454A MX2023008454A (es) 2021-01-18 2022-01-18 Derivados sintéticos de ácido ursólico y métodos de uso de estos.

Country Status (14)

Country Link
US (1) US20240140986A1 (es)
EP (1) EP4277916A1 (es)
JP (1) JP2024504637A (es)
KR (1) KR20230147077A (es)
CN (1) CN117015548A (es)
AU (1) AU2022208727A1 (es)
CA (1) CA3204434A1 (es)
CL (1) CL2023002064A1 (es)
CO (1) CO2023010422A2 (es)
IL (1) IL304530A (es)
MX (1) MX2023008454A (es)
PE (1) PE20231661A1 (es)
TW (1) TW202245795A (es)
WO (1) WO2022155614A1 (es)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS58486B1 (sr) 2008-01-11 2019-04-30 Reata Pharmaceuticals Inc Sintetički triterpenoidi i metode njihove upotrebe u tretmanu bolesti
BRPI0911422B8 (pt) * 2008-04-18 2021-05-25 Reata Pharmaceuticals Inc compostos moduladores inflamatórios antioxidantes, composição farmacêutica e usos dos mesmos
PL2276493T3 (pl) 2008-04-18 2019-05-31 Reata Pharmaceuticals Inc Antyoksydacyjne modulatory stanu zapalnego: pochodne kwasu oleanolowego z amino- i innymi modyfikacjami przy C-17
TW201004627A (en) 2008-04-18 2010-02-01 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: novel derivatives of oleanolic acid
CN102164941B (zh) 2008-04-18 2015-05-27 里亚塔医药公司 抗氧化剂炎症调节剂:具有饱和c环的齐墩果酸衍生物
UY33946A (es) 2011-03-11 2012-08-31 Reata Pharmaceuticals Inc Derivados de c4-monometil triterpenoides y sus métodos de uso
PT2841445T (pt) * 2012-04-27 2017-09-01 Reata Pharmaceuticals Inc Derivados de 2,2-difluoropropionamida de metil bardoxolona, formas polimorfas e métodos de uso dos mesmos
WO2013188818A1 (en) * 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
PE20150627A1 (es) * 2012-09-10 2015-06-04 Reata Pharmaceuticals Inc Derivados de c17-alcandiilo y alquendiilo del acido oleanolico y sus metodos de uso
WO2014040056A1 (en) 2012-09-10 2014-03-13 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
TW201936625A (zh) * 2013-04-24 2019-09-16 美商艾伯維有限公司 甲基巴多索龍之2,2-二氟丙醯胺衍生物、其多晶形及其使用方法
EA201890767A1 (ru) * 2015-09-23 2019-09-30 Рита Фармасьютикалз, Инк. C4-модифицированные производные олеаноловой кислоты для ингибирования il-17 и других применений
US10953020B2 (en) * 2016-11-08 2021-03-23 Reata Pharmaceuticals, Inc. Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof
US20220017566A1 (en) * 2018-09-28 2022-01-20 Sichuan Haisco Pharmaceutical Co., Ltd. Terpinoid derivatives and uses thereof

Also Published As

Publication number Publication date
WO2022155614A1 (en) 2022-07-21
AU2022208727A1 (en) 2023-08-03
PE20231661A1 (es) 2023-10-17
CO2023010422A2 (es) 2023-08-28
JP2024504637A (ja) 2024-02-01
CA3204434A1 (en) 2022-07-21
EP4277916A1 (en) 2023-11-22
US20240140986A1 (en) 2024-05-02
KR20230147077A (ko) 2023-10-20
TW202245795A (zh) 2022-12-01
CN117015548A (zh) 2023-11-07
IL304530A (en) 2023-09-01
CL2023002064A1 (es) 2023-12-29

Similar Documents

Publication Publication Date Title
CR20220363A (es) Compuestos tricíclicos sustituidos
MX2022012780A (es) Inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras) triciclicos fusionados.
CR20220312A (es) Compuestos tricíclicos sustituidos
CR20200614A (es) Compuestos heterocíclicos como inmunomoduladores
WO2018049152A8 (en) Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
WO2019199861A3 (en) Hemp extract for treatment of pain in animals
WO2018154145A3 (en) Retinol replacement in skin treatment
MX2021012549A (es) Derivados de tetrahidro-1h-ciclopenta[cd]indeno como inhibidores del factor inducible por hipoxia-2(alfa).
MX2021010888A (es) Derivados heteroaromaticos y aromaticos heterobiciclicos para el tratamiento de trastornos relacionados con ferroptosis.
GEP20227434B (en) 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer
PH12019501371A1 (en) PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF RORy AND OTHERS USES
MX2022006086A (es) Derivados de piridopirimidinona como antagonistas de ahr.
CR20220160A (es) Derivados de piridazin-3(2h)-ona fusionados con azol
CR20240059A (es) Compuestos tricíclicos como inhibidores de kras.
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
MX2023008677A (es) Derivados de urolitinas y métodos para su uso.
MX2021007780A (es) Composiciones y metodos para tratar trastornos neurodegenerativos.
MX2022014925A (es) Moduladores de il-17a.
MX2022014924A (es) Moduladores de il-17a.
WO2019043450A3 (en) COSMETIC COMPOSITIONS HAVING ANTIOXIDANT PROPERTIES
AU2018260628A1 (en) Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions
MX2022011576A (es) Moduladores de nlrp3.
MX2022007595A (es) Triterpenoides sinteticos con sustituyentes a base de nitrogeno en c-17 y metodos de uso de los mismos.
MX2023008454A (es) Derivados sintéticos de ácido ursólico y métodos de uso de estos.
MX2022000308A (es) Formulacion de nanoparticulas de inhibidor de bcl-2.